Farzana Haque
Validation of the HULL Score clinical prediction rule for unsuspected pulmonary embolism in ambulatory cancer patients
Haque, Farzana; Ryde, Jessamine; Broughton, Laura; Huang, Chao; Sethi, Sifut; Stephens, Andrew; Pillai, Annet; Mirza, Shagufta; Brown, Victoria; Avery, Ged; Bozas, Georgios; Maraveyas, Anthony
Authors
Jessamine Ryde
Dr Laura Broughton Laura.Broughton@hull.ac.uk
Research Development Assistant
Dr Chao Huang C.Huang@hull.ac.uk
Reader in Statistics
Sifut Sethi
Andrew Stephens
Annet Pillai
Shagufta Mirza
Victoria Brown
Ged Avery
Georgios Bozas
Anthony Maraveyas
Abstract
Background Clinical prediction rules (CPRs) developed to predict adverse outcomes of suspected pulmonary embolism (PE) and facilitate outpatient management have limitations in discriminating outcomes for ambulatory cancer patients with unsuspected PE (UPE). The HULL Score CPR uses a 5-point scoring system incorporating performance status and self-reported new or recently evolving symptoms at UPE diagnosis. It stratifies patients into low, intermediate and high risk for proximate mortality. This study aimed to validate the HULL Score CPR in ambulatory cancer patients with UPE. Patients and methods 282 consecutive patients managed under the UPE-acute oncology service in Hull University Teaching Hospitals NHS Trust were included from January 2015 to March 2020. The primary end-point was all-cause mortality, and outcome measures were proximate mortality for the three risk categories of the HULL Score CPR. Results 30-day, 90-day and 180-day mortality rates for the whole cohort were 3.4% (n=7), 21.1% (n=43) and 39.2% (n=80), respectively. The HULL Score CPR stratified patients into low-risk (n=100, 35.5%), intermediate-risk (n=95, 33.7%) and high-risk (n=81, 28.7%) categories. Correlation of the risk categories with 30-day mortality (area under the curve (AUC) 0.717, 95% CI 0.522–0.912), 90-day mortality (AUC 0.772, 95% CI 0.707–0.838), 180-day mortality (AUC 0.751, 95% CI 0.692–0.809) and overall survival (AUC 0.749, 95% CI 0.686–0.811) was consistent with the derivation cohort. Conclusion This study validates the capacity of the HULL Score CPR to stratify proximate mortality risk in ambulatory cancer patients with UPE. The score uses immediately available clinical parameters and is easy to integrate into an acute outpatient oncology setting.
Citation
Haque, F., Ryde, J., Broughton, L., Huang, C., Sethi, S., Stephens, A., …Maraveyas, A. (2023). Validation of the HULL Score clinical prediction rule for unsuspected pulmonary embolism in ambulatory cancer patients. ERJ Open Research, 9(3), Article 00651-2022. https://doi.org/10.1183/23120541.00651-2022
Journal Article Type | Article |
---|---|
Acceptance Date | Jan 25, 2023 |
Online Publication Date | Feb 2, 2023 |
Publication Date | May 1, 2023 |
Deposit Date | Apr 12, 2023 |
Publicly Available Date | May 3, 2023 |
Journal | ERJ Open Research |
Electronic ISSN | 2312-0541 |
Publisher | European Respiratory Society |
Peer Reviewed | Peer Reviewed |
Volume | 9 |
Issue | 3 |
Article Number | 00651-2022 |
DOI | https://doi.org/10.1183/23120541.00651-2022 |
Keywords | Pulmonary and Respiratory Medicine |
Public URL | https://hull-repository.worktribe.com/output/4260425 |
Publisher URL | https://openres.ersjournals.com/content/early/2023/01/26/23120541.00651-2022 |
Files
Published article
(481 Kb)
PDF
Publisher Licence URL
http://creativecommons.org/licenses/by-nc/4.0
Copyright Statement
Copyright ©The authors 2023
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
You might also like
Abstract A020: Calcitonin receptor-like receptor is expressed in blood vessels in clear cell renal cell carcinoma and upregulated in endothelial cells co-cultured with tumor cells
(2023)
Presentation / Conference Contribution
Abstract B001: Calcitonin receptor-like receptor agonists induce p44/42 MAPK phosphorylation in VEGF-A-stimulated human blood endothelial cells after bevacizumab treatment
(2023)
Presentation / Conference Contribution
Abstract 224: Establishing de novo platform for whole genome sequencing of pancreatic cyst fluid for early detection and diagnosis of pancreatic cancer
(2023)
Presentation / Conference Contribution
Downloadable Citations
About Repository@Hull
Administrator e-mail: repository@hull.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search